(0.33%) 5 116.80 points
(0.33%) 38 367 points
(0.37%) 15 987 points
(-0.94%) $83.06
(5.25%) $2.02
(0.35%) $2 355.40
(0.53%) $27.68
(4.11%) $960.00
(-0.27%) $0.932
(-0.46%) $10.97
(-0.57%) $0.796
(1.66%) $93.40
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 14.92%
@ $9.20
発行日: 16 3月 2024 @ 04:39
リターン: -30.49%
前回のシグナル: 3月 15 - 22:44
前回のシグナル:
リターン: 0.77 %
Live Chart Being Loaded With Signals
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases...
Stats | |
---|---|
本日の出来高 | 379 781 |
平均出来高 | 2.46M |
時価総額 | 438.70M |
EPS | $0 ( 2024-02-22 ) |
次の収益日 | ( $-0.410 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.40 |
ATR14 | $0.0130 (0.20%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-14 | Mossler Mark | Buy | 27 430 | Stock Option (Right to Buy) |
2024-02-14 | Mossler Mark | Buy | 18 290 | Common Stock |
2024-04-01 | Anderson Kenneth Carl | Buy | 1 389 | Common Stock |
2024-04-01 | Dubin Glenn | Buy | 1 358 | Common Stock |
2024-04-01 | Grogan Donna Roy | Buy | 1 697 | Common Stock |
INSIDER POWER |
---|
59.70 |
Last 98 transactions |
Buy: 4 435 645 | Sell: 1 001 966 |
ボリューム 相関
C4 Therapeutics, Inc. 相関
10 最も負の相関 | |
---|---|
STAY | -0.951 |
CCRC | -0.95 |
SGEN | -0.947 |
PAE | -0.944 |
EBSB | -0.94 |
PTOC | -0.931 |
DSPG | -0.93 |
PPYAU | -0.929 |
RAM | -0.92 |
LMNR | -0.918 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
C4 Therapeutics, Inc. 相関 - 通貨/商品
C4 Therapeutics, Inc. 財務諸表
Annual | 2023 |
収益: | $20.76M |
総利益: | $13.02M (62.72 %) |
EPS: | $-2.67 |
FY | 2023 |
収益: | $20.76M |
総利益: | $13.02M (62.72 %) |
EPS: | $-2.67 |
FY | 2022 |
収益: | $31.10M |
総利益: | $23.52M (75.65 %) |
EPS: | $-2.59 |
FY | 2021 |
収益: | $45.79M |
総利益: | $0.00 (0.00 %) |
EPS: | $-1.730 |
Financial Reports:
No articles found.
C4 Therapeutics, Inc.
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。